The existence of FDA-approved, brain-penetrant 5HT2A antagonists such as pimavanserin and mirtazapine highlights the possibility of repurposing these agents in glioma treatment, which should be further studied in prospective clinical trials. This evidence concerns the gene HTR2A and central nervous system cancer.